drugset / Trial / NCT06234956
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
Phase 2
Completed
242 enrolled
Hipra Scientific, S.L.U
Asphalion · collabVHIR · collabVeristat, Inc. · collab
NaSingle-groupOpen-labelPrevention
Summary
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents. In this study a total of 300 adolescents from 12 to less than 18 years will be enrolled and followed for 12 months.
Timeline
- Start
- 2023-06-08
- Primary completion
- 2025-09-09
- Completion
- 2025-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SELVACOVATEIN | Vaccine | — | — |